Startup Announces Successful Trial Of CBD As Ulcerative Colitis Therapy

A company producing treatments for medical conditions based on cannabidiol (CBD) has announced the successful completion of its trial of a therapy for ulcerative colitis. 

CBD, a non-psychoactive chemical produced by the cannabis plant, has been shown to help alleviate health issues like inflammation, anxiety, skin conditions, arthritis and joint pain. 

CannaMore Biotechs conducted the Phase 2a clinical trial in order to assess the safety, tolerability and efficacy of its CBD-based enema formulation, IcBD-01, as a potential treatment for ulcerative colitis. 

The Bnei Brak-based company says the three-month trial showed promising results in the majority of the 10 participants. According to the company, most of the participants reported substantial improvements in symptoms, including reduced abdominal pain and better overall wellbeing. 

The study was conducted at Meir Hospital in Kfar Saba and led by its gastroenterology specialist Prof. Timna Naftali. The hospital is operated by Clalit, Israel’s largest health maintenance organization and a research partner for CannaMore.

“The results of this trial are highly encouraging and support the potential of IcBD-01 as an effective treatment for ulcerative colitis,” said Naftali. 

“We observed significant improvements in both clinical outcomes and patient-reported symptoms, which marks a promising step forward in our ongoing efforts to develop innovative CBD-based therapies. This treatment may provide a safe and effective solution for the subgroup of patients with ulcerative proctitis, where there is an unmet need for effective and safe treatment,” she said.